imiquimod has been researched along with ginsenoside rg1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; He, Q; Long, J; Shi, Q; Zhang, B | 1 |
| Ma, X; Mao, J; Zhang, H; Zhu, J | 1 |
2 other study(ies) available for imiquimod and ginsenoside rg1
| Article | Year |
|---|---|
Ginsenoside Rg1 abolish imiquimod-induced psoriasis-like dermatitis in BALB/c mice via downregulating NF-κB signaling pathway.
Topics: Animals; Dermatitis; Disease Models, Animal; Down-Regulation; Ginsenosides; Humans; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Signal Transduction; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2019 |
Ginsenoside Rg1 ameliorates psoriasis-like skin lesions by suppressing proliferation and NLRP3 inflammasomes in keratinocytes.
Topics: Animals; Cell Proliferation; Ginsenosides; Humans; Imiquimod; Inflammasomes; Keratinocytes; Ki-67 Antigen; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; Quality of Life; Reactive Oxygen Species; Sincalide | 2022 |